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Heart failure (HF) afﬂicts about 5 million people and causes 300 000 deaths a year in the United States
alone. An integral part of the pathogenesis of HF is cardiac remodelling, and the signalling events that
regulate it are a subject of intense research. Cardiac remodelling is the sum of responses of the heart to
causes of HF, such as ischaemia, myocardial infarction, volume and pressure overload, infection, inﬂam-
mation, and mechanical injury. These responses, including cardiomyocyte hypertrophy, myocardial
ﬁbrosis, and inﬂammation, involve numerous cellular and structural changes and ultimately result in
a progressive decline in cardiac performance. Pharmacological and genetic manipulation of cultured
heart cells and animal models of HF and the analysis of cardiac samples from patients with HF are all
used to identify the molecular and cellular mechanisms leading to the disease. Protein kinase C (PKC)
isozymes, a family of serine–threonine protein kinase enzymes, were found to regulate a number of
cardiac responses, including those associated with HF. In this review, we describe the PKC isozymes
that play critical roles in speciﬁc aspects of cardiac remodelling and dysfunction in HF.
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1. Protein kinase C: an introduction
Protein kinase C (PKC) is a group of closely related serine–
threonine protein kinases, further classiﬁed as (1) the clas-
sical PKCs (a, bI, bII, and g), the diacylglycerol (DAG)-,
and calcium-dependent enzymes, (2) the novel PKCs (d, e,
u, and h), which require DAG, but not calcium, for activity,
and (3) the atypical PKCs (z, l), which are not stimulated by
DAG or calcium, but are stimulated by other lipid-derived
second messengers.
1.1 Protein kinase C in the normal and diseased
myocardium
PKC isozymes are expressed in all tissues. mRNA expression
of a, d, e, h, and zPKCs is found in rat cultured cardiomyo-
cytes.
1,2 Abundant expression of both bI and bIIPKC in
human and rat cardiomyocytes has also been reported,
3–6
whereas the mouse myocardium expresses low levels of
these bPKCs.
7 Further species-speciﬁc differences in the
expression of h, u, and ePKC were also reported.
8 There-
fore, the interpretation of animal studies must be done
with caution as species to species variation in PKC
isozyme expression is substantial. Western blot analyses of
human cardiac tissue using polyclonal antibodies (PKC-a,
-bI, -bII -1,- d,-g, and -h) or monoclonal antibodies
(PKC-l,- m, and -u) demonstrated the presence of these iso-
zymes in human heart tissue.
4 This study also demonstrated
differences in the distribution of PKC isozymes between the
atria and ventricles. The calcium-dependent isozymes, a,
bI, and bIIPKC, reside predominantly in the ventricle,
whereas d and zPKC are mainly expressed in the atria and
1 and lPKC are evenly distributed in both atria and
ventricles.
PKC isozymes are involved in a variety of chronic cardiac
diseases
9 as well as in acute cardiac injuries and precondi-
tioning.
10 We and others have demonstrated that select
PKC isozymes contribute to heart failure (HF).
9,11–16
Isozyme-selective tools that were generated in the past
few years, including pharmacological peptide regulators
(Figure 1) and use of genetic manipulation and RNAi, demon-
strated that the same isozyme may mediate different func-
tions in acute vs. chronic heart diseases. For example, 1PKC
activation prior to MI is protective,
17 whereas in
hypertension-induced HF 1PKC activation is detrimental.
15
Here we review the role of PKC isozymes in cardiac remodel-
ling and HF.
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HF is a clinical syndrome characterized by impaired ability
of the left ventricle to ﬁll or eject blood.
18 Currently, the
life-time risk to develop HF after the age of 40 is 20%
for men or women.
19 The aetiology of HF is diverse and
includes ischaemia, hypertension, idiopathic cardiomyopa-
thy, bacterial endocarditis, congenital cardiovascular
defects, and valvular diseases. However, the most common
aetiologies of HF are coronary artery disease and myocardial
infarction (MI);
20 each year, about one million people suffer
from acute MI and within 6 years, HF will disable about
300 000 of these patients.
19
2.1 Cardiac remodelling
Cardiac remodeling is an early and progressive response of
the heart to insults, such as ischaemia, volume and pressure
overload, infection, inﬂammation, mechanical injury, and
stimulation by cytokines and enzymes. Depending on the
extent of cardiomyocyte loss by these insults, ﬁbroblast pro-
liferation and collagen secretion, namely ﬁbrosis, is trig-
gered to maintain the shape and structure of the
myocardium. Injuries to coronary vasculature, stimulation
by stress factors, and ﬁbrosis also result in changes in struc-
ture and function of blood vessels. Inﬁltration of inﬂamma-
tory cells into the jeopardized myocardium leads to
continuous release of cytokines, chemokines, enzymes,
and growth factors, which further contribute to the remo-
delling process. Therefore, a better understanding of the
cellular and molecular basis of cardiac remodelling events,
including adaptive and maladaptive hypertrophy, perivascu-
lar and interstitial ﬁbrosis, and inﬂammation, will further
clarify the pathogenesis of HF.
3. Cardiac hypertrophy: adaptive
and maladaptive responses
Adaptive cardiac hypertrophy is characterized by an
increase in heart mass and wall thickening due to an
increase in cardiac myocyte size and protein synthesis, and
is associated with improved cardiac function.
21 If cardiac
overload continues, a transition from adaptive to maladap-
tive hypertrophy takes place. This is associated with left
ventricle dilation, a decrease in contractile elements, and
reduced cardiac output.
21 The use of culture studies,
animal models, and human samples with HF provided
insight into the role of PKC in this pathology.
3.1 Protein kinase C isozymes in cardiomyocyte
hypertrophy in cell culture models
Neonatal cardiomyocytes are commonly used to study
hypertrophic signalling. Whether this model represents
developmental hypertrophy only or whether it also provides
an appropriate model of pathological hypertrophy is
debated. However, because cardiac remodelling activates
many of the cardiac embryonic developmental programs,
this culture model may provide an insight into HF.
A variety of stimulants, such as phorbol myristate acetate
(PMA), angiotensin-II (AngII), phenylephrine (PE), and
Figure 1 Protein kinase C peptide modulators. (A) Inactive protein kinase C (gray) undergoes a conformational change exposing both the RACK-binding site and
the active site when diacylglycerol (DG) or PMA are elevated. Active protein kinase C (blue) binds to its RACK (red), anchoring the activated isozyme near its
substrate (green). Phosphorylation (P) of that substrate leads to the physiological responses of that isozyme. (B) Alternatively, a peptide that mimics the RACK-
binding site, pseudo-RACK (CRACK, yellow) can also cause these conformational changes. CRACK binds to protein kinase C with a lower afﬁnity than the intact
RACK and thus does not always occupy the RACK-binding site on the enzyme. During the time that the peptide is not bound, the activated enzyme may bind to its
RACK (red), resulting in anchoring of the activated isozyme near its substrate (green) followed by substrate phosphorylation (P) and physiological responses. This
process is isozyme-speciﬁc. (C) A peptide corresponding to the RACK-biding site on protein kinase C (orange) inhibits translocation and function of its correspond-
ing isozyme. The translocation inhibitor peptide binds to the RACK and blocks binding of the activated isozyme to that RACK. Therefore, the physiological
responses mediated by that isozyme are blocked.
S.S. Palaniyandi et al. 230Table 1 The role of individual protein kinase C isozymes in cardiac remodelling and heart failure
Model Cardiac phenotype PKC isozyme Stimulus/treatment Main response Reference
Streptozotocin-induced diabetic rats Hypertrophy cPKCs Increased cardiac ßIIPKC activity
86
Transgenic mice Hypertrophy 1PKC Cardiac-speciﬁc expression of 1PKC
inhibitor, 1V1
Lethal dilated cardiomyopathy
36
Transgenic mice Hypertrophy 1PKC Cardiac-speciﬁc expression of 1PKC
activator, c1RACK
Concentric cardiac hypertrophy
36
Transgenic mice Hypertrophy 1PKC Over-expression constitutively
active 1PKC
Concentric cardiac hypertrophy
87
Transgenic mice Hypertrophy cPKCs and nPKCs Active calcineurin over-expression Increased cardiac a and bPKC translocation
88
Pressure-overload aortic banding rats Hypertrophy cPKCs and nPKCs Increased cardiac bIPKC, bIIPKC, 1PKC, and uPKC
translocation
89
Transgenic mice Hypertrophy bIIPKC and 1PKC Over-expression constitutively
active 1PKC
Pathological cardiac hypertrophy
90
Adult rat ventricle myocyte Hypertrophy 1PKC Pharmacological: 1V1-2 (speciﬁc
1PKC isozyme inhibitor)
Attenuated isoproterenol-induced apoptosis
91
Dahl salt-sensitive hypertensive rats Hypertrophy cPKCs and nPKCs Increased cardiac 1PKC levels in compensatory stage
and bIIPKC levels during cardiac dysfunction
14
Pressure-overload aortic banding rats Hypertrophy aPKC and dPKC Increased cardiac levels of aPKC and dPKC
92
Adult guinea pig heart (ex vivo) Hypertrophy cPKCs and nPKCs Perfusion with angiotensin II Increased cardiac aPKC, bIIPKC, and gPKC
93
Dahl Salt hypertensive rats Hypertrophy/heart
failure
cPKCs, nPKCs, and
aPKCs
Increased cardiac levels of cPKC, nPKC, and aPKC
94
Pressure-overload heart failure rats Hypertrophy/heart
failure
aPKC and 1PKC Sustained treatment with ACE
inhibitor
ACE inhibitor attenuates increased aPKC and 1PKC
translocation
95
bIIPKC transgenic mice Hypertrophy/heart
Failure
bIIPKC Cardiac-speciﬁc bIIPKC
over-expression
Pathological cardiac hypertrophy
32
aPKC transgenic mice Hypertrophy/heart
failure
aPKC Wild-type and dominant negative
aPKC expression
Increased contractility and cardioprotection
29,96
Human end-stage dilated or
ischaemic cardiomyopathy
Heart failure cPKCs Increased cardiac bPKC activity
3
Human end-stage Dilated
cardiomyopathy
Heart failure cPKCs and nPKCs Increased cardiac bIIPKC levels
4
Dahl Salt hypertensive rats Heart failure cPKCs and nPKCs Increased cardiac bIPKC, bIIPKC levels, and
translocation
14
MLP transgenic mice Heart failure Ro-31-8220 (cPKC and 1PKC
inhibitors)
PKC inhibition reverted cardiac hypertrophy
34
Dahl Salt hypertensive rats Fibrosis/heart
failure
1PKC Sustained treatment with 1V1-2
(speciﬁc 1PKC inhibitor)
Decreased cardiac ﬁbrosis
15
bIIPKC transgenic mice Hypertrophy/
ﬁbrosis
bIIPKC Cardiac-speciﬁc over-expression of
bIIPKC
Pathological cardiac hypertrophy and ﬁbrosis
11
Pressure-overload aortic banding
mice
Fibrosis dPKC and 1PKC 1PKC knock-out mouse Increased ﬁbrosis
54
Neonatal rat cardiac ﬁbroblast Fibroblast
proliferation
dPKC and zPKC TGFb1 and isozyme-speciﬁc
inhibitors
Stimulated cardiac ﬁbroblast proliferation
39
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1endothelin-1 (ET1), are used to induce hypertrophy in
culture (Table 1). PMA, which activates both conventional
and novel PKC isozymes, or transfection of either wild-type
(WT) or dominant-negative (DN) aPKC mutant demonstrated
that aPKC is both necessary and sufﬁcient to induce certain
features of cardiomyocyte hypertrophy including increases
in protein synthesis, the protein-to-DNA ratio, and cell
surface area.
22 Further, aPKC antisense treatment reduced
PE-induced increases in a-actin mRNA and atrial natriuretic
peptide (ANP) secretion, but not PE-induced b-myosin heavy
chain, ANP, or B-type natriuretic peptide (BNP) gene
expression,
23 therefore causing a loss of only some to the
pathological hypertrophic markers. In other studies, overex-
pression of aPKC increased cell surface area, [
3H]-leucine
incorporation, and mRNA levels of ANP,
24 together indicating
that aPKC activation induced cardiomyocyte hypertrophy in
cultured cardiomyocytes. We found that bI and bIIPKC are
required for PMA-induced cardiomyocyte hypertrophy.
25
Later, we substantiated that RBCK-1 (RBCC protein that
interacts with bIPKC) is essential for PE-induced cardiomyo-
cyte hypertrophy.
26 Overexpression of RBCK1 increased the
cardiac myocyte cell surface by 50% in the absence of PE
treatment and the bI- and bIIPKC-speciﬁc peptide inhibitors
prevented that effect.
26 A role for 1PKC has also been
suggested; treatment with 1PKC antisense reduced
myotrophin-induced stimulation of protein synthesis in neo-
natal myocytes.
27 This study also found that d and zPKC are
not involved in this process. Therefore, at least four PKC iso-
zymes, a, bI, bII, and 1 induce hypertrophy in neonatal
cardiac myocytes.
3.2 Protein kinase C in cardiac hypertrophy
of animal models
aPKC expression and activity were unaltered in early HF but
were up-regulated in two distinct rat models of end-stage
HF.
28 Depletion of myocardial aPKC by gene knock-out
increased myocardial contractility, whereas transgenic over-
expression of aPKC led to marked ventricular dysfunction
and alterations in Ca
2þ homeostasis.
29 Phosphorylation
studies suggest that aPKC depresses myoﬁlament contracti-
lity through phosphorylation of cTnI and/or cTnT.
30 Skinned
left-ventricular myocytes isolated from rats subjected to
chronic (8–9 months) pressure overload or MI-induced HF
in rats supported these conclusions; myoﬁlament function
is severely depressed in these experimental HF models.
28
In an earlier study, bPKC levels were elevated in
hypertension-induced HF rats.
14 Treatment with
angiotensin-receptor blocker improved cardiac function
and decreased bPKC activation and levels.
14 In a recent
study, we found that a selective inhibition of bIIPKC
improved cardiac function and calcium handling in rats
with post-MI HF, and improved function and prolonged the
life span of rats with hypertension-induced HF.
31 In addition
to reducing mortality, selective and sustained inhibition of
bIIPKC by bIIV5-3 (a selective inhibitor of bIIPKC
25) in rats
with post-MI HF improved cardiac function compared with
that prior to treatment initiation.
31 The beneﬁcial effect
was associated with enhanced calcium handling and normal-
ization of the levels and phosphorylation of SERCA2, NCX,
and troponin I.
31 Further, the reduction in cardiomyocyte
width, HW/BW, and increased fractional shortening follow-
ing bIIV5-3 treatment in rats with end-stage pathological
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S.S. Palaniyandi et al. 232hypertrophy were observed, thereby indicating that bIIPKC
activation is a critical mediator of cardiac hypertrophy in
rats (Figure 2).
Although the basal level of bPKC in the hearts of adult
mice is low,
13 a number of reports suggest that bPKC is an
important isozyme in cardiac diseases in mice, as well.
11,32
Targeted over-expression of bIIPKC in mice resulted in
cardiac hypertrophy with myocardial dysfunction similar to
that of HF.
11 Over-expression of activated bIIPKC in neonatal
mice is fatal and, in the case of adult mice, it induces hyper-
trophy and myocardial dysfunction.
32 Pharmacological inhi-
bition of a and bPKC by Ro-32-0432 improved myocardial
contractility and left-ventricular developed pressure in
mouse hearts.
34 In contrast to these observations, another
study using bPKC knockout mice demonstrated no role for
bPKC in HF development.
35 Hence the role of bPKC in
cardiac hypertrophy in mice using genetic manipulation is
controversial.
Transgenic mice that express 1 or dPKC activator or inhibi-
tor peptides only postnatally and only in cardiac myocytes
(using the aMHC promoter)
36 revealed potential redundant
roles for these enzymes in cardiac hypertrophy. Mice expres-
sing the 1PKC-selective inhibitor, 1V1, developed dilated
eccentric cardiomyopathy and HF, an effect associated
with a 10% increase in myocyte size when compared with
the non-transgenic mice. Transgenic mice expressing the
1PKC-selective activator, c1RACK, exhibited normal
cardiac function, increased cardiac muscle mass (concentric
hypertrophy) (Figure 2), and had no increase in ﬁbrosis.
However, upon examination of cardiac myocyte cell size, it
was found that myocytes were 10% smaller (P , 0.01).
Since the number and size of other cardiac cells remained
unchanged, this indicated that the number of cardiomyo-
cytes has increased. As a result of 1PKC activation, hyper-
plasia, a phenomenon restricted mainly to perinatal
cardiac development, may have occurred.
36 These data
suggest that 1PKC signalling may be part of a compensatory
signalling pathway that is pro-proliferative at least during
early post-natal development. This conclusion was further
supported by work examining a cross between Gaq over-
expressing mice, which develop a dilated cardiomyopathy
phenotype, and transgenic mice with mild activation of
1PKC. The double-transgenic progeny exhibited a reduction
in cardiac hypertrophy and an improvement in cardiac func-
tion compared with the Gaq over-expressing mice.
37 There-
fore, 1PKC appears to be a positive modulator of
compensatory cardiac hypertrophy in this mouse model.
Because in this model activation of 1PKC and Gaq were
induced from day 1 after birth, the phenotype may reﬂect
restoration of 1PKC activity in the Gaq-phenotype.
37
Figure 2 Protein kinase C isozymes are closely involved with different remodelling events in myocardial infarction induced-heart failure. Heart failure pro-
gression is noticeably characterized by cardiac remodelling, whereas speciﬁc protein kinase C isozyme plays a crucial role in this time-related event. Cardiomyo-
cyte death, inﬂammation, cardiac hypertrophy, and ﬁbrosis are directly regulated by speciﬁc protein kinase C isozymes such as a, bII, d, and 1 protein kinase C as
depicted in the ﬁgure. The TUNEL staining image is from Murriel et al. (2004)
33 and the hypertrophy image from www.ipmc.cnrs.fr.
PKC in heart failure 233In hypertensive rats, 1PKC levels increase during the com-
pensatory stage of cardiac hypertrophy,
14 but 1PKC was det-
rimental in this response. Further activation of 1PKC (by a
sustained treatment with the PKC-selective activator,
c1RACK) increased cardiac ﬁbrosis and HF, whereas 1PKC
inhibition (by sustained treatment with the 1PKC-selective
inhibitor, 1V1-2) prolonged survival, reduced hypertrophy,
excessive ﬁbrosis, vascular remodelling, and inﬂammation
and corrected cardiac dysfunction.
15,16
Thus studies in mice and rats are not in agreement,
suggesting either species differences and/or differences
due to the tools that were used (pharmacological vs.
genetic manipulation of the animals) as well as the timing
of regulation of PKC (i.e. before and/or during the disease
course.). A summary of a number of studies using pharmaco-
logical and genetic approaches to determine the role of PKC
isozymes in hypertrophy and in HF is provided in Table 1.
3.3 Protein kinase C in human hypertrophy
and heart failure
Although animal studies were inconclusive using genetic
manipulations and pharmacologcial PKC modulators
(Table 1), studies characterizing the level and activity of
PKC isozymes in human HF
3,4 provide insight into which iso-
zymes should be focused on as therapeutic targets. For
instance, aPKC was found to be critical in cardiomyocyte
hypertrophy by knock-out and over-expression studies in
mice.
22,28,29 Though activation of aPKC is critical in mouse
model of HFs,
29,34 activated aPKC levels were found to be
low in samples of patients with end-stage HF when com-
pared with normal subjects.
4 Further this study demon-
strated that aPKC is activated in the myocardium of
patients with aortic stenosis, a condition in which heart
functions are not jeopardized. In contrast, both Bowling
et al.
3 and Simonis et al. also
4 found a signiﬁcant 70 and
150% increase in activation of bPKC, respectively and imuno-
histochemical staining and mRNA labelling indicated that
bPKC is elevated in cardiomyocytes of human HF
samples.
3,4 LY333531, an inhibitor reported initially to be
speciﬁc for bPKC,
38 reduced total PKC activity in membrane
fractions of failing hearts by 209 pmol min
21mg
21 suggesting
that bPKC constitutes for the majority PKC activity in the
failing hearts. Together, these studies indicate that
changes in bPKC correlate better with the human HF,
suggesting that focusing on this PKC isozyme in considering
therapeutic intervention is advisable.
4. Cardiac ﬁbrosis
Fibrosis refers to accumulation of ﬁbroblasts due to
increased proliferation, migration, and adhesion of ﬁbro-
blasts to the site of injury and/or leading to the accumu-
lation of extracellular matrix proteins, such as collagen,
by augmented release from ﬁbroblasts or reduced degra-
dation of collagen. Replacement ﬁbrosis, interstitial ﬁbrosis,
and perivascular ﬁbrosis are different types of myocardial
ﬁbrotic processes, which may occur sequentially or simul-
taneously. However, an excess of any of these processes
interferes with myocardial metabolism, particularly the
supply of oxygen and removal of cellular metabolic waste,
leading to myocardial malfunctioning, and thus posing detri-
mental effects to failing hearts. Excess ﬁbrosis can also
decrease cardiac elasticity and thus affect cardiac contrac-
tion. A variety of pathological stressors, such as ischaemia
and hypertension, can trigger cardiac ﬁbrosis. The occur-
rence of cardiac ﬁbrosis requires a series of coordinated
molecular and cellular events that alter the properties of
the extracellular matrix (ECM) and cardiac ﬁbroblasts. PKC
has been shown to regulate the speciﬁc events leading to
the deposition of collagen.
4.1 Protein kinase C isozymes in cultured
cardiac ﬁbroblasts
a, bI, bII, d, 1, and zPKC have been found in both neonatal
and adult cardiac ﬁbroblasts and the non-selective PKC acti-
vator, PMA, inhibits basal and TGFb-induced thymidine
incorporation in these rat ﬁbroblasts.
39 Using isozyme-
selective inhibitors, we found that dPKC and zPKC have
opposing roles in TGFb-induced ﬁbroblast proliferation,
whereas other PKC isozymes have no role in this process.
39
We showed that selective inhibition of zPKC blocked
TGF-b1-induced cardiac ﬁbroblast proliferation. In contrast,
the dPKC-selective peptide inhibitor, dV1-1, had an opposite
effect to that of the zPKC inhibitor; it increased
TGF-b1-induced proliferation. Therefore, d and zPKC act
downstream of TGF-b1, yielding opposing roles in ﬁbroblast
proliferation.
PKC regulates the levels and activity of matrix metallo-
proteinases (MMP), a family of zinc-containing proteases,
that degrade ECM and facilitate the motility of cardiac ﬁbro-
blasts.
40–44 For example, a and bIPKC increase the activity
of MMP-9, but not MMP-2, primarily through the
JNK-dependent pathway.
44 Other PKCs, such as u and
zPKC, increase both MMP-2 and MMP-9 via ERK and NFkB
pathways in adult rat cardiac ﬁbroblasts.
44 Ang II binds to
angiotensin-type 1 receptor and activates PKC
45 which ulti-
mately leads to ﬁbroblast proliferation.
46–48 The pro-
proliferative effects of other proﬁbrotic stimuli, such as
ET-1, were also attenuated by inhibition of PKC with either
chelerythrine or staurosporine in neonatal cardiac
ﬁbroblasts.
49
A critical role for 1PKC in regulating ﬁbroblast adhesion
and migration has also been reported; the effect of Ang II
treatment, which induces adhesion and migration in
cardiac ﬁbroblasts, was blocked by PKC inhibition, and was
abolished in cardiac myoﬁbroblasts obtained from 1PKC
knockout mice.
48 Additional mechanistic studies demon-
strated that 1PKC forms a tight complex with b1-integrin
to regulate the interaction between the cell and ECM.
50–52
These ﬁndings corroborate a role for 1PKC in mediating
cardiac ﬁbroblast adhesion and migration.
4.2 Protein kinase C in cardiac ﬁbrosis, in vivo
A role for PKC in cardiac ﬁbrosis has also been suggested by
in vivo studies using animal models of HF. Inhibition of clas-
sical PKCs, namely, a and bPKC, by ruboxistaurin attenuated
pathological ﬁbrosis and improved cardiac function follow-
ing MI in rats, suggesting a role for classical PKCs in ﬁbrogen-
esis in the heart.
12 In a recent study, selective bIIPKC
inhibition with bIIV5-3 attenuated collagen deposition in
the remote region of the myocardium of post-MI HF rats
53
(Figure 2). Hearts from 1PKC knock-out mice demonstrated
elevated interstitial ﬁbrosis when subjected to pressure
overload by transverse aortic constriction.
54 In contrast,
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inhibitor, 1V1-2, suppressed cardiac ﬁbrosis and ameliorated
cardiac function, in part by inhibiting MMP-2 activity, in a rat
model of hypertension-induced HF.
15 Moreover, c1RACK, an
activator of 1PKC, augmented the ﬁbrotic process and accel-
erated mortality in these hypertensive animals. Further, in a
rat or mouse cardiac transplantation model, we found that
inhibition of 1PKC by 1V1-2 also blocked parenchymal ﬁbro-
sis and the increase in TGF-b1 in the grafted heart, corro-
borating a role for 1PKC in cardiac ﬁbrosis in vivo
55,56
(Figure 2). The contradicting ﬁndings using 1PKC knock-out
mice and pharmacological regulation of 1PKC in rats
suggest that regulation by PKC isozymes may differ accord-
ing to the aetiology of ﬁbrosis, the species, and/or the
extent of activation of compensatory mechanisms (i.e.
1PKC null mice have 60% increase in dPKC activity, which
may have compensated for 1PKC,
45 whereas there is no
change in the levels or activity of any PKC isozyme, other
than 1PKC, when using the 1PKC-selective inhibitor
15).
(These and other studies are also listed in Table 1.). Under-
standing the exquisite control of cardiac ﬁbrosis by PKC
could potentially translate to novel effective treatments
for cardiac dysfunction and HF.
5. Cardiac inﬂammation
Irrespective of aetiology, myocardial inﬂammation is an
integral part of HF (i.e. inﬂammation is found in the myocar-
dium following ischaemia, cardiac infection, autoimmune
response, pressure and volume overload, etc.). Though
inﬂammation is often secondary to the trigger for speciﬁc
cardiac disease, inﬂammatory cells are a constant source
for cytokines, enzymes, and growth factors, which regulate
remodelling events such as hypertrophy, ﬁbrosis, and
vascularization.
5.1 Protein kinase C in cardiac inﬂammation
Numerous in vitro studies point out the role of PKC isozymes
in pro-inﬂammatory mediator production (transcription and
translation) and release.
57–62 One aspect of cardiac inﬂam-
mation that is better described is the induction of cell
damage by pro-inﬂammatory cytokines in cardiac diseases
or cardiac cells. For example, TNF-a induced apoptosis in
coronary vascular endothelial cells seems to be a
PKC-mediated event.
63 Sustained inhibition of 1PKC by
1V1-2 decreased the inﬁltration of inﬂammatory cells into
the myocardium in the hearts of hypertensive rats with
HF.
16 In an MI-induced HF rat model, bIIV5-3, the speciﬁc
bIIPKC inhibitor, also attenuated inﬁltration of inﬂammatory
cells
53 (Figure 2). Both of these PKC inhibitors attenuated
degranulation of mast cells (MCs), the important inﬂamma-
tory cells that are involved in HF progression (Figure 2).
Likewise, TNF-a production in macrophages is blocked by
PKC inhibition with bisindolylmaleimide, a pan PKC inhibitor,
or by Go-6976, a classical PKC inhibitor.
64 Further studies on
the role of PKC isozymes in the function of important inﬂam-
matory cells such as macrophages, T-cells, MCs, and neutro-
phils in HF progression are needed, because these cells are
an integral part of cardiac remodelling and HF.
65,66
6. Downstream targets of protein kinase C in
cardiac remodelling
As discussed earlier, PKC isozymes regulate ﬁbrosis, inﬂam-
mation, and cardiac muscle dysfunction and a number of
downstream mediators of PKC effects have been identiﬁed.
Stimulation of primary cultures of adult feline cardiomyo-
cytes with ET-1, PE, PMA, or insulin resulted in phosphoryl-
ation and activation of several pro-survival kinases,
including mTOR (AKA mammalian Target of Rapamycin; at
S2248) and S6K1 (at and T389 S421/T424) via PKC activation.
Expression of DN-1PKC abolished ET-1-stimulated mTOR and
S6K1 phosphorylation, but not insulin-stimulated S6K1 phos-
phorylation. ET-1- and insulin-stimulated mTOR and S6K1
phosphorylation in cardiomyocytes was inhibited by
expression of DN-dPKC or pre-treatment with rottlerin, a
dPKC inhibitor. However, treatment with Go ¨6976, a speciﬁc
classical PKC (cPKC) inhibitor did not affect mTOR/S6K1
activation. This study demonstrates that 1 and dPKC acti-
vate mTOR and S6 kinase and subsequently lead to cardio-
myocyte hypertrophy in cultured feline cardiomyocytes.
67
Another important kinase that has been implicated in hyper-
trophic signalling is glycogen synthase kinase (GSK).
Up-regulation of GSK-3a suppresses cardiac growth and
pressure-overload-induced cardiac hypertrophy in mice.
Knock-down of GSK-3a increased the phosphorylation of
ERK (extracellular signal-regulated kinase), an effect that
was inhibited by pharmacological inhibitors of 1 and dPKC
and MEK (mitogen-activated protein kinase kinase),
suggesting that GSK-3a inhibits ERK through
PKC-MEK-dependent mechanisms and further regulates
cardiac hypertrophy.
68 In another study, involvement of
PKC in TGF-b1-induced cardiac hypertrophic responses by
activating TAK1 (another member of the mitogen-activated
kinase kinase kinase family) and ultimately activating tran-
scription factor (ATF). The PKC inhibitors, GO6976 and
GF109203X, blocked TGF-b1-induced TAK1 kinase activity
and subsequent downstream signalling pathways including
ATF-2 phosphorylation, leading to suppression of ATF-2 tran-
scriptional activity.
69 The transcription factor GATA-4 plays a
key role in ANF promoter activation in response to pro-
hypertrophic Ang II through PKC activation and ultimately
resulting in enhanced DNA binding activity.
70 Inhibition of
PKC prevents nuclear export of histone deacetylase 5
(HDAC5, a protein regulating myogenesis) in response to
hypertrophic agonists. Moreover, a mutation in HDAC5 is
refractory to PKC activation. Protein kinase D (PKD),
another downstream effector of PKC, directly phosphory-
lates HDAC5 and stimulates its nuclear export.
71 The
stretch-induced increase in cardiac hypertrophy is blocked
by inhibition of the small G protein, Rho, or by overexpres-
sion of dominant negative a and dPKC, suggesting that a and
dPKC are both required for stretch-induced hypertrophy,
through Rho GTPase-mediated signalling pathways. Also,
phosphorylation of MEK1/ERK1/2 and the MEK kinase,
MKK4, and jun kinase, JNK, was inhibited by over-expression
of dominant negative a and dPKC.
72
Myocyte dysfunction in aPKC transgenic mice was caused
by alterations in Ca
2þ homeostasis.
29 As discussed, in mice,
aPKC depresses myoﬁlament contractility through site-
speciﬁc phosphorylation of cTnT at the threonine-206
residue in cardiomyocytes.
30 On the other hand, a decreased
myoﬁlament responsiveness to Ca2þ was seen in the
PKC in heart failure 235myocardium of bIIPKC overexpressing transgenic mice as
well as a signiﬁcant increase in the degree of phosphoryl-
ation of troponin I. The depressed cardiomyocyte function
improved after the sequential superfusion of LY333531, a
bPKC inhibitor. This study shows that bIIPKC-mediated phos-
phorylation of troponin I in vivo may decrease myoﬁlament
Ca2þ responsiveness, and thus causes cardiomyocyte
dysfunction.
73
OtherproteintargetsofPKCarethoseinvolvedinECMregu-
lation. 1PKC regulates b1-integrin complex formation with
ECM and further participates in the ﬁbrotic events.
50–52
a, bI, 1, u, and zPKC isozymes activate different MMPs to
degradeECM,therebyfacilitatingthemotilityofcardiacﬁbro-
blasts
44 and inﬂammatory cells. In inﬂammatory cells, PKC
activation enhances the transcription of cytokine production
through phosphorylation of the inhibitor of transcription
factor NFkB, IkB.
74 A summary of these and other downstream
targets of PKC activation leading to HF is given in Figure 3.
7. Summary and conclusion: should protein
kinase C be a target for heart failure
treatment?
Preventing maladaptive cardiac remodelling is a goal of
therapy for HF.
75 In this review, we provide evidence that
select PKC isozymes play different roles in many aspects of
cardiac remodelling in HF (see Table 1 and Figures 2 and
3). Because modulators of PKC isozymes are already in clini-
cal trials for a variety of indications,
76–84 it may now be
possible to consider using such PKC isozyme regulators to
treat human HF. Although PKC isozymes are present in
many tissues, recent clinical trials suggest that systemic
delivery of inhibitors and activators of PKC isozymes is
well tolerated (see studies with the bPKC small molecule
inhibitor,
77,78 with the peptide inhibitor of dPKC.
76 Further,
new developments in drug delivery suggest that organ-
selective delivery may also be possible in the future, for
example by delivering slow drug releasing particles to the
organ of interest.
85 Therefore, clinical trials with PKC inhibi-
tors to address HF should be considered using either sys-
temic or cardiac-speciﬁc drug delivery. Further in vivo
studies using animal models, including larger animals like
dogs, sheep, and pigs, will help guide the identiﬁcation of
the right PKC isozymes that should serve as therapeutic
targets for the treatment of pathological cardiac remodel-
ling and HF in humans.
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